Literature DB >> 7706496

Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera.

N Després1, G Talbot, B Plouffe, G Boire, H A Ménard.   

Abstract

RA is the most frequent and most destructive inflammatory arthropathy. Rheumatoid factors, in spite of their lack of disease specificity, are important serological markers for RA and appear important in its immunopathogenesis as well. In search of more disease-specific autoimmune systems, we have screened a human placenta lambda gt11 cDNA expression library using selected sera from patients with classical erosive RA. We have identified one clone (RA-1) that is recognized by three of five screening sera. The 950-bp insert shows a complete nucleotide sequence homology to the cDNA encoding the two COOH-terminal domains of calpastatin. The deduced open reading frame of the RA-1 cDNA predicts a 284-amino acid protein, with a calculated mol wt of 35.9 kD. Calpastatin is the natural inhibitor of calpains, which are members of the cysteine proteinases recently implicated in joint destruction in rheumatic diseases. The two domains encoded by the RA-1 clone each contain the structural features associated with the inhibitory activity of human calpastatin. By Western blotting, 45.5% or 21/44 RA sera specifically recognized both the fusion and the cleaved recombinant protein. This is in contrast to 4.7% (2/43) in nonrheumatoid sera and 0/10 in normal sera. Anticalpastatin autoantibodies could represent a disease-associated marker in chronic erosive arthritis of the rheumatoid type and could hypothetically play a dual pathogenic role, directly via an immune interference and indirectly through an immune complex mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706496      PMCID: PMC295733          DOI: 10.1172/JCI117870

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity. Expression of the cDNA fragments in Escherichia coli.

Authors:  Y Emori; H Kawasaki; S Imajoh; Y Minami; K Suzuki
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

2.  Isolation and characterization of cDNA clones for human erythrocyte beta-spectrin.

Authors:  J T Prchal; B J Morley; S H Yoon; T L Coetzer; J Palek; J G Conboy; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint.

Authors:  I Fukui; K Tanaka; T Murachi
Journal:  Biochem Biophys Res Commun       Date:  1989-07-31       Impact factor: 3.575

6.  Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases.

Authors:  B Lenarcic; D Gabrijelcic; B Rozman; M Drobnic-Kosorok; V Turk
Journal:  Biol Chem Hoppe Seyler       Date:  1988-05

7.  The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis.

Authors:  N Després; G Boire; F J Lopez-Longo; H A Ménard
Journal:  J Rheumatol       Date:  1994-06       Impact factor: 4.666

8.  Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.

Authors:  D Gabrijelcic; A Annan-Prah; B Rodic; B Rozman; V Cotic; V Turk
Journal:  J Clin Chem Clin Biochem       Date:  1990-03

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage.

Authors:  D D Dean; J Martel-Pelletier; J P Pelletier; D S Howell; J F Woessner
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

View more
  15 in total

Review 1.  Insights into rheumatoid arthritis derived from the Sa immune system.

Authors:  H A Ménard; E Lapointe; M D Rochdi; Z J Zhou
Journal:  Arthritis Res       Date:  2000-08-17

2.  Autoantibodies directed against the protease inhibitor calpastatin in psoriasis.

Authors:  Y Matsushita; Y Shimada; S Kawara; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

3.  Serum samples of patients with rheumatoid arthritis contain a specific autoantibody to "denatured" aldolase A in the osteoblast-like cell line, MG-63.

Authors:  F Ukaji; I Kitajima; T Kubo; C Shimizu; T Nakajima; I Maruyama
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

4.  Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.

Authors:  M Tanaka; M Kishimura; S Ozaki; F Osakada; H Hashimoto; M Okubo; M Murakami; K Nakao
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum.

Authors:  C Masson-Bessière; M Sebbag; J J Durieux; L Nogueira; C Vincent; E Girbal-Neuhauser; R Durroux; A Cantagrel; G Serre
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

6.  Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma.

Authors:  M Labrador; A Algueró; C Díaz; C Geli; E Pérez; J García-Valero; J L Rodriguez-Sanchez; C Gelpí
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 7.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 8.  Tissue-associated autoantigens in rheumatoid arthritis. Tissue-antigens detected by autoantibodies in synovial fluid and sera of RA patients.

Authors:  P von Landenberg; J Schölmerich
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

9.  Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signals.

Authors:  Mikiko Iguchi-Hashimoto; Takashi Usui; Hajime Yoshifuji; Masakazu Shimizu; Shio Kobayashi; Yoshinaga Ito; Kosaku Murakami; Aoi Shiomi; Naoichiro Yukawa; Daisuke Kawabata; Takaki Nojima; Koichiro Ohmura; Takao Fujii; Tsuneyo Mimori
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

10.  Posttranslational Protein Modification in the Salivary Glands of Sjögren's Syndrome Patients.

Authors:  Rafael Herrera-Esparza; Mayra Rodríguez-Rodríguez; María Elena Pérez-Pérez; Martha Adriana Badillo-Soto; Felipe Torres-Del-Muro; Juan José Bollain-Y-Goytia; Deyanira Pacheco-Tovar; Esperanza Avalos-Díaz
Journal:  Autoimmune Dis       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.